Applied BioCode Receives FDA 510(k) Clearance for Syndromic Respiratory Pathogen Panel
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Jan 6, 2020--
Applied BioCode announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for its BioCode® Respiratory Pathogen Panel (RPP) for use on the BioCode® MDx-3000 System. The BioCode® RPP tests nasopharyngeal swabs for of the most common viruses and bacteria, including Influenza A and subtypes H1, H1N1 2009pdm and H3, Influenza B, Respiratory Syncytial Virus A/B, Parainfluenza virus types 1, 2, 3, and 4, Human Metapneumovirus A/B, Adenovirus, Rhinovirus/Enterovirus, Coronavirus (229E, OC43, HKU1, and NL63), Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis.
The BioCode® MDx-3000 offers “flexible ordering” and “flexible reporting” capabilities to address variation in test ordering patterns and potential changes in reimbursement. In addition to the RPP, the company also has an FDA-cleared 17-target BioCode® Gastrointestinal Pathogen Panel (GPP). The system allows users to run the RPP and GPP combo panels at the same time, providing both time and labor saving efficiencies. The walk-away BioCode® MDx-3000 system, with the capability to process up to 188 samples in an 8-hour shift, is designed for moderate to high volume laboratories to improve lab workflow, reduce labor and cost. It is an alternative to high cost, low throughput cartridge-based molecular test systems. The BioCode® MDx-3000 also offers a User Defined Mode where laboratories can develop their own multiplex assays.
About Applied BioCode
Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The company has combined digital barcodes with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets. Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200106005058/en/
CONTACT: Applied BioCode
Dr. Winston Z. Ho
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH FDA INFECTIOUS DISEASES MANUFACTURING GENERAL HEALTH OTHER MANUFACTURING BIOTECHNOLOGY
SOURCE: Applied BioCode
Copyright Business Wire 2020.
PUB: 01/06/2020 07:05 AM/DISC: 01/06/2020 07:05 AM